One mechanism by which AML cells develop resistance to venetoclax is the upregulation of other anti-apoptotic proteins, including MCL-1, which can sequester BAX and BIM, thus compensating for the loss of BCL-2 function [11,17,18,19]. The gene discussed is BAX; the disease is acute myeloid leukemia.